USANA Health Sciences (NYSE:USNA – Get Free Report) announced its quarterly earnings results on Tuesday. The company reported $0.54 earnings per share for the quarter, missing the consensus estimate of $0.65 by ($0.11), RTT News reports. The company had revenue of $212.87 million for the quarter, compared to analyst estimates of $218.64 million. USANA Health Sciences had a return on equity of 11.26% and a net margin of 6.29%. During the same period in the prior year, the business posted $0.89 earnings per share. USANA Health Sciences updated its FY 2024 guidance to 2.400-2.550 EPS.
USANA Health Sciences Stock Down 0.7 %
Shares of USANA Health Sciences stock traded down $0.29 on Thursday, hitting $44.20. 2,727 shares of the company were exchanged, compared to its average volume of 79,518. The company has a 50-day moving average price of $46.34 and a 200 day moving average price of $47.09. The stock has a market capitalization of $842.01 million, a price-to-earnings ratio of 13.86, a price-to-earnings-growth ratio of 1.38 and a beta of 0.90. USANA Health Sciences has a 1-year low of $40.51 and a 1-year high of $69.60.
Insider Activity at USANA Health Sciences
In other news, insider Paul A. Jones sold 2,714 shares of USANA Health Sciences stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $48.66, for a total transaction of $132,063.24. Following the transaction, the insider now owns 6,266 shares in the company, valued at approximately $304,903.56. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, insider Paul A. Jones sold 2,714 shares of the stock in a transaction that occurred on Wednesday, May 22nd. The stock was sold at an average price of $48.66, for a total value of $132,063.24. Following the completion of the transaction, the insider now directly owns 6,266 shares in the company, valued at $304,903.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Daniel A. Macuga sold 3,791 shares of the business’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $47.14, for a total transaction of $178,707.74. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 31,591 shares of company stock valued at $1,458,098. 0.33% of the stock is currently owned by insiders.
Analysts Set New Price Targets
Read Our Latest Stock Analysis on USANA Health Sciences
USANA Health Sciences Company Profile
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.
Further Reading
- Five stocks we like better than USANA Health Sciences
- What Is WallStreetBets and What Stocks Are They Targeting?
- Beauty Retailer Stock Brings Early Christmas for Value Investors
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Ford Stock EPS Disappoints, Shares Plummet After-Hours
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- How Much Should You Be Investing? Try Our Calculators
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.